Vitae
Pharmaceuticals, Inc. VTAE, a clinical-stage biotechnology company,
today announced that it has initiated the second part of its Phase 1
multiple ascending dose clinical trial of VTP-43742 in psoriatic patients.
VTP-43742 is the Company's wholly owned and first-in-class RORt
inhibitor product candidate for the treatment of autoimmune disorders,
potentially including psoriasis, psoriatic arthritis, ankylosing
spondylitis, rheumatoid arthritis and multiple sclerosis, as well as
numerous orphan diseases.
In this proof-of-concept study, Vitae will evaluate the safety,
tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of
multiple ascending doses of VTP-43742 in patients with moderate to severe
psoriasis. The primary endpoint measure will be a percent change from
baseline in the PASI (Psoriasis Area and Severity Index) score at four
weeks. Top-line clinical efficacy results are expected by the end of 2015.
This proof-of-concept part of the Phase 1 multiple ascending dose trial
overlaps with the first part of the study currently being conducted in
healthy human volunteers, which the Company initiated in August 2015.
"The initiation of this second part of our multiple ascending dose
proof-of-concept trial marks Vitae's first assessment of the clinical
efficacy of our novel and first-in-class RORt inhibitor in a
psoriatic patient population. This is a major step for the Company, and for
determining whether VTP-43742 can provide a safe, effective and convenient
oral treatment option for this patient population whose needs may not be
satisfied by the current standards of care," said Dr. Richard Gregg, Chief
Scientific Officer of Vitae.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in